Drug Profile
Mycobacterium cell wall-DNA Complex - Liminal BioSciences
Alternative Names: EN3348; MCC; MCC/HA; MCNA; Mycobacterium Cell Wall-DNA Complex/hyaluronic acid; Mycobacterium phlei cell-wall - nucleic acid complex; Prostacidin; UrocidinLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Bioniche Life Sciences
- Developer Bioniche Life Sciences; Endo Pharmaceuticals; Liminal BioSciences
- Class Antiandrogens; Antineoplastics; DNA
- Mechanism of Action Apoptosis stimulants; Immunostimulants; Interleukin 12 stimulants; Interleukin 6 stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bladder cancer
- No development reported Cancer; Infections; Peritoneal cancer; Prostate cancer; Solid tumours
Most Recent Events
- 12 Apr 2021 No development reported - Preregistration for Bladder cancer (Second-line therapy or greater) in USA (Intravesicular) (Liminal Bioscience pipeline, April 2021)
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)